Echosens is highlighting the link between liver disease and diabetes and urging individuals and communities to help raise awareness about the impact of diabetes.
Read More
The most profitable ancillary you’ve never heard of – Why NAFLD is the income repair solution your practice needs.
Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
NAFLD includes a range of diseases from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Children as young as five are also developing fatty liver disease from too little physical activity and excessive consumption of sugars, sodas, fructose, and corn syrup. Fortunately, NAFLD is reversible if caught early and accompanied by lifestyle changes.
Gastroenterologist and hepatologist, Stephen Harrison, M.D., talks about the alarming growth in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the United States.
Traditionally a disease that primarily attracted the focused attention of hepatologists, nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, has recently raised alarms across a spectrum of health care providers and payers
Traditionally a disease that primarily attracted the focused attention of hepatologists, nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, has recently raised alarms across a spectrum of health care providers and payers
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH).
